|
US5811524A
(en)
*
|
1995-06-07 |
1998-09-22 |
Idec Pharmaceuticals Corporation |
Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
|
|
FR2758331B1
(fr)
*
|
1997-01-14 |
1999-03-05 |
Univ Bourgogne |
Nouveaux moyens pour le diagnostic, la prevention et le traitement vis-a-vis de contaminations ou d'infections par des virus a tropisme muqueux
|
|
US7033589B1
(en)
*
|
1997-02-20 |
2006-04-25 |
Biogen Idec Ma Inc. |
γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
|
|
US6893636B2
(en)
*
|
1997-02-20 |
2005-05-17 |
Biogen Idec Ma Inc. |
Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
|
|
WO1999012553A1
(en)
*
|
1997-09-08 |
1999-03-18 |
Idec Pharmaceuticals Corporation |
Methods for producing human antibodies in scid mice using dendritic cells
|
|
JP4334141B2
(ja)
*
|
1998-04-20 |
2009-09-30 |
グリカート バイオテクノロジー アクチェンゲゼルシャフト |
抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
|
|
US6900299B1
(en)
*
|
1999-03-11 |
2005-05-31 |
University Of South Florida |
Interrupting the interaction of intercellular adhesion molecule-1 and respiratory syncytial virus for prevention and treatment of infection
|
|
CO5280147A1
(es)
*
|
1999-05-18 |
2003-05-30 |
Smithkline Beecham Corp |
Anticuerpo humano monoclonal
|
|
GB9918788D0
(en)
*
|
1999-08-10 |
1999-10-13 |
Leuven K U Res & Dev |
Antithrombotic effect of platelet glycoprotein 1b blocking monoclonal Fab fragments
|
|
US6680209B1
(en)
*
|
1999-12-06 |
2004-01-20 |
Biosite, Incorporated |
Human antibodies as diagnostic reagents
|
|
CA2398466A1
(en)
*
|
2000-01-27 |
2001-08-02 |
Medimmune, Inc. |
Ultra high affinity neutralizing antibodies
|
|
AU2002219944B2
(en)
*
|
2000-11-28 |
2008-02-21 |
Medimmune, Llc |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
US7229619B1
(en)
|
2000-11-28 |
2007-06-12 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
EP1255560B1
(de)
|
2000-02-02 |
2008-10-29 |
UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE |
Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
|
|
JP2003525061A
(ja)
*
|
2000-03-01 |
2003-08-26 |
メディミューン,インコーポレイテッド |
高効力組換え抗体およびその産生法
|
|
JP2003531866A
(ja)
*
|
2000-05-03 |
2003-10-28 |
メディミューン,インコーポレイテッド |
抗体を用いた呼吸器疾患の組合せ治療法
|
|
US6855493B2
(en)
*
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
US7179900B2
(en)
*
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
|
US6818216B2
(en)
|
2000-11-28 |
2004-11-16 |
Medimmune, Inc. |
Anti-RSV antibodies
|
|
EP1355919B1
(de)
*
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
|
|
US20040096451A1
(en)
*
|
2002-07-25 |
2004-05-20 |
Young James F. |
Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
|
|
WO2002060484A1
(en)
|
2001-01-31 |
2002-08-08 |
Idec Pharmaceuticals Corporation |
Use of cd23 antagonists for the treatment of neoplastic disorders
|
|
WO2002076507A2
(en)
*
|
2001-03-23 |
2002-10-03 |
Genentech, Inc. |
Uses of opg ligand to modulate immune responses
|
|
EP1383800A4
(de)
*
|
2001-04-02 |
2004-09-22 |
Idec Pharma Corp |
ZUSAMMEN MIT GnTIII EXPRIMIERTE REKOMBINANTE ANTIKÖRPER
|
|
WO2002102303A2
(en)
*
|
2001-05-01 |
2002-12-27 |
Medimmune, Inc. |
Crystals and structure of synagis fab
|
|
JP4435563B2
(ja)
*
|
2001-07-10 |
2010-03-17 |
バイオジェン アイデック インク |
アポトーシスプロセスの阻害および細胞性能の改善
|
|
EP1423510A4
(de)
|
2001-08-03 |
2005-06-01 |
Glycart Biotechnology Ag |
Antikörperglykosylierungsvarianten mit erhöhter antikörperabhängiger zellulärer zytotoxizität
|
|
US7306919B1
(en)
*
|
2001-10-31 |
2007-12-11 |
Thornthwaite Jerry T |
Antigen-antibody cancer recognition system
|
|
WO2003063767A2
(en)
*
|
2001-11-02 |
2003-08-07 |
Centocor |
Rsv proteins, antibodies, compositions, methods and uses
|
|
JP2005517401A
(ja)
*
|
2002-02-11 |
2005-06-16 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
免疫欠損非ヒト哺乳動物宿主におけるヒト抗体の産生
|
|
CA2482333A1
(en)
*
|
2002-02-11 |
2003-08-21 |
Alexion Pharmaceuticals, Inc. |
Human antibodies for therapy against vaccinia or smallpox
|
|
CA2480419A1
(en)
*
|
2002-03-28 |
2003-10-09 |
Yamanouchi Pharmaceutical Co., Ltd. |
Antiopoietin-related growth factor
|
|
US7132100B2
(en)
*
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
|
US7425618B2
(en)
*
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
|
AU2003243443B2
(en)
*
|
2002-06-21 |
2008-11-06 |
Centocor, Inc. |
Method for generating monoclonal antibodies
|
|
KR100604038B1
(ko)
*
|
2002-08-02 |
2006-07-24 |
주식회사유한양행 |
항체 중쇄 발현벡터
|
|
JP4033390B2
(ja)
*
|
2002-10-30 |
2008-01-16 |
独立行政法人科学技術振興機構 |
不死化ナチュラルキラー細胞株
|
|
RS20050577A
(sr)
*
|
2003-01-27 |
2007-09-21 |
Biogen Idec Ma Inc., |
PREPARATI I POSTUPCI ZA TRETIRANjE KANCERA KORIŠĆENjEM IGSF9 I LIV-1
|
|
US20040208869A1
(en)
*
|
2003-01-30 |
2004-10-21 |
Medimmune, Inc. |
Uses of anti-integrin alphanubeta3 antibody formulations
|
|
PL1606409T3
(pl)
|
2003-03-19 |
2011-02-28 |
Biogen Ma Inc |
Białko wiążące receptor Nogo
|
|
US20060257972A1
(en)
*
|
2003-03-31 |
2006-11-16 |
Takashi Ishihara |
Purification of human monoclonal antibody and human polyclonal antibody
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
US7070786B2
(en)
*
|
2003-06-06 |
2006-07-04 |
Centocor, Inc. |
RSV proteins, antibodies, compositions, methods and uses
|
|
MXPA05014155A
(es)
|
2003-06-27 |
2006-05-25 |
Abgenix Inc |
Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos.
|
|
US20050239700A1
(en)
*
|
2003-10-14 |
2005-10-27 |
Biogen Idec Inc. |
Treatment of cancer using antibodies to LRRC15
|
|
WO2005047327A2
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
|
|
US20060246079A1
(en)
|
2003-11-14 |
2006-11-02 |
Morrow Phillip R |
Neutralizing human antibodies to anthrax toxin
|
|
WO2005056052A1
(en)
|
2003-11-14 |
2005-06-23 |
Avanir Pharmaceuticals |
Neutralizing human antibodies to anthrax toxin generated by recall technology
|
|
WO2005081749A2
(en)
*
|
2004-01-23 |
2005-09-09 |
Avanir Pharmaceuticals, Inc. |
Neutralizing human antibodies to anthraxtoxin
|
|
CN1914226B
(zh)
*
|
2003-11-25 |
2012-02-01 |
达纳-法伯癌症研究院有限公司 |
SARS-CoV抗体及其使用方法
|
|
WO2005092926A2
(en)
|
2004-03-19 |
2005-10-06 |
Amgen Inc. |
Reducing the risk of human and anti-human antibodies through v gene manipulation
|
|
PT1776136E
(pt)
|
2004-06-24 |
2012-12-05 |
Biogen Idec Inc |
Tratamento de estados que envolvem desmielinização
|
|
EP1789070B1
(de)
|
2004-08-03 |
2012-10-24 |
Biogen Idec MA Inc. |
Taj in der neuronalen funktion
|
|
US20060063187A1
(en)
*
|
2004-09-15 |
2006-03-23 |
Hotamisligil Gokhan S |
Modulation of XBP-1 activity for treatment of metabolic disorders
|
|
WO2006041970A2
(en)
*
|
2004-10-08 |
2006-04-20 |
Abbott Biotechnology Ltd. |
Treatment of respiratory syncytial virus (rsv) infection
|
|
CA2585891A1
(en)
*
|
2004-10-29 |
2006-05-11 |
Medimmune, Inc. |
Methods of preventing and treating rsv infections and related conditions
|
|
CA2593212A1
(en)
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Cripto binding molecules
|
|
JP5238936B2
(ja)
|
2005-03-25 |
2013-07-17 |
ジーアイティーアール,インク. |
Gitr結合分子およびその使用
|
|
ES2547463T3
(es)
*
|
2005-06-17 |
2015-10-06 |
Merck Sharp & Dohme Corp. |
Moléculas de unión a ILT3 y usos de las mismas
|
|
SI1904104T1
(sl)
|
2005-07-08 |
2013-12-31 |
Biogen Idec Ma Inc. |
Protitelesa SP35 in njihova uporaba
|
|
WO2008048230A2
(en)
*
|
2005-08-15 |
2008-04-24 |
Emory University |
Methods of identifying biological targets and instrumentation to identify biological targets
|
|
EP1959979A4
(de)
|
2005-11-04 |
2010-01-27 |
Biogen Idec Inc |
Verfahren zur förderung des axonen-wachstums und des überlebens dopaminergischer neuronen
|
|
WO2007062037A2
(en)
*
|
2005-11-21 |
2007-05-31 |
Laboratoires Serono Sa |
Compositions and methods of producing hybrid antigen binding molecules and uses thereof
|
|
US20090175872A1
(en)
|
2005-12-02 |
2009-07-09 |
Biogen Idec Ma Inc. |
Treatment of Conditions Involving Demyelination
|
|
NZ600075A
(en)
*
|
2005-12-09 |
2013-12-20 |
Amc Amsterdam |
Means and methods for influencing the stability of antibody producing cells
|
|
ES2367322T3
(es)
|
2005-12-16 |
2011-11-02 |
Ribovax Biotechnologies Sa |
Métodos para obtener células inmortalizadas que secretan anticuerpos.
|
|
EP2526968A3
(de)
|
2006-01-27 |
2013-05-22 |
Biogen Idec MA Inc. |
Nogo-Rezeptorantagonisten
|
|
US20100040606A1
(en)
*
|
2006-03-06 |
2010-02-18 |
Symphogen A/S |
Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
|
|
TW200813086A
(en)
|
2006-05-11 |
2008-03-16 |
Hoffmann La Roche |
Immunereconstituted mouse
|
|
WO2008094176A2
(en)
*
|
2006-06-19 |
2008-08-07 |
Tolerx, Inc. |
Ilt3 binding molecules and uses therefor
|
|
US20080171344A1
(en)
*
|
2006-12-22 |
2008-07-17 |
Kapsner Kenneth P |
Methods, Kits and Materials for Diagnosing Disease States by Measuring Isoforms or Proforms of Myeloperoxidase
|
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
|
GEP20125693B
(en)
|
2007-01-09 |
2012-11-26 |
Biogen Idec Inc |
Sp35 antibodies and usage thereof
|
|
CA2678628A1
(en)
*
|
2007-03-06 |
2008-09-12 |
Symphogen A/S |
Recombinant antibodies for treatment of respiratory syncytial virus infections
|
|
US7807168B2
(en)
*
|
2007-04-10 |
2010-10-05 |
Vaccinex, Inc. |
Selection of human TNFα specific antibodies
|
|
EP1997830A1
(de)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
|
|
PT2175884T
(pt)
|
2007-07-12 |
2016-09-21 |
Gitr Inc |
Terapias de combinação empregando moléculas de ligação a gitr
|
|
BRPI0817257A2
(pt)
*
|
2007-09-24 |
2015-06-16 |
Univ Vanderbilt |
Anticorpos moniclonais para vírus sincital respiratório e usos dos mesmos
|
|
WO2009062050A2
(en)
|
2007-11-08 |
2009-05-14 |
Neogenix Oncology, Inc. |
Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
|
|
BRPI0819063A2
(pt)
*
|
2007-11-27 |
2020-08-18 |
The University Of British Columbia |
método para tratamento de artrite, anticorpo, hibridoma, antagonista de 14-3-3, usos de um antagonista de 14-3-3, composições farmacêuticas, método para redução da expressão de mmp no sinóvio de um paciente e usos de uma composição farmacêutica
|
|
KR100938998B1
(ko)
*
|
2008-01-08 |
2010-01-28 |
(주) 에이프로젠 |
호흡기 신시티움 바이러스에 대한 항체
|
|
US20090233295A1
(en)
*
|
2008-01-29 |
2009-09-17 |
Elias Georges |
Trim59 directed diagnostics for neoplastic disease
|
|
LT2285408T
(lt)
|
2008-06-05 |
2019-01-25 |
Ablynx N.V. |
Aminorūgščių sekos, nukreiptos prieš viruso apvalkalo baltymus, ir tokias sekas turintys polipeptidai, skirti virusinių ligų gydymui
|
|
EP2315779A2
(de)
|
2008-07-09 |
2011-05-04 |
Biogen Idec MA Inc. |
Antikörper gegen lingo oder fragmente davon enthaltende zusammensetzungen
|
|
EP2145621A1
(de)
|
2008-07-16 |
2010-01-20 |
Stephan Lück |
Verhinderung der Dehydrierung und Reduzierung der gluconeogenetischen Verluste von Aminosäuren durch Propan-1,2,3-Triol
|
|
JP5575377B2
(ja)
*
|
2008-07-18 |
2014-08-20 |
シスメックス株式会社 |
抗rsウイルスモノクローナル抗体を用いたrsウイルス検出用キット及びイムノクロマトグラフィー用試験具、並びに新規な抗rsウイルスモノクローナル抗体
|
|
US8775090B2
(en)
|
2008-12-12 |
2014-07-08 |
Medimmune, Llc |
Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
|
|
CN102341411A
(zh)
|
2008-12-31 |
2012-02-01 |
比奥根艾迪克Ma公司 |
抗-淋巴细胞毒素抗体
|
|
WO2010111180A1
(en)
|
2009-03-24 |
2010-09-30 |
Teva Biopharmaceuticals Usa, Inc. |
Humanized antibodies against light and uses thereof
|
|
CN102459332B
(zh)
*
|
2009-06-05 |
2015-08-19 |
埃博灵克斯股份有限公司 |
用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体
|
|
EP4183412B1
(de)
|
2009-07-15 |
2024-08-14 |
GlaxoSmithKline Biologicals SA |
Rsv-f-proteinzusammensetzungen und verfahren zu ihrer herstellung
|
|
MX2012001882A
(es)
|
2009-08-13 |
2012-04-11 |
Crucell Holland Bv |
Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
|
|
EP2477658A2
(de)
*
|
2009-09-16 |
2012-07-25 |
Duke University |
Hiv-1-antikörper
|
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
|
WO2011064382A1
(en)
|
2009-11-30 |
2011-06-03 |
Ablynx N.V. |
Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
|
WO2011119920A2
(en)
|
2010-03-25 |
2011-09-29 |
Oregon Health & Science University |
Cmv glycoproteins and recombinant vectors
|
|
SI2400298T1
(sl)
*
|
2010-05-28 |
2013-11-29 |
F. Hoffmann-La Roche Ag |
Postopek kultivacije posamezne B-celice in izdelava specifičnih protiteles
|
|
PT2591006T
(pt)
|
2010-07-09 |
2019-07-29 |
Bioverativ Therapeutics Inc |
Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
|
|
EP2591000B1
(de)
|
2010-07-09 |
2017-05-17 |
Janssen Vaccines & Prevention B.V. |
Antikörper gegen humanes respiratorisches syncytialvirus (rsv) und ihre verwendung
|
|
EP2422618A1
(de)
|
2010-08-27 |
2012-02-29 |
Technologie Integrale Ltd. |
Tiermodell zur Beurteilung der Wirksamkeit eines HIV-Impfstoffs
|
|
US9956236B2
(en)
|
2011-02-07 |
2018-05-01 |
Cornell University |
Methods for increasing immune responses using agents that directly bind to and activate IRE-1
|
|
EP3699286A1
(de)
|
2011-04-20 |
2020-08-26 |
The Trustees of the University of Pennsylvania |
Dosierpläne und zusammensetzungen zur aav-vermittelten passiven immunisierung von luftbürtigen krankheitserregern
|
|
RS56748B1
(sr)
|
2011-05-13 |
2018-03-30 |
Glaxosmithkline Biologicals Sa |
Pre-fuzioni rsv f antigeni
|
|
CA2838833A1
(en)
|
2011-06-10 |
2012-12-13 |
Biogen Idec Ma Inc. |
Pro-coagulant compounds and methods of use thereof
|
|
ES2667425T3
(es)
|
2011-06-10 |
2018-05-10 |
Oregon Health & Science University |
Glucoproteínas y vectores recombinantes de CMV
|
|
WO2013012733A1
(en)
|
2011-07-15 |
2013-01-24 |
Biogen Idec Ma Inc. |
Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
|
|
AU2012216792A1
(en)
|
2011-09-12 |
2013-03-28 |
International Aids Vaccine Initiative |
Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
|
|
WO2013040307A1
(en)
*
|
2011-09-16 |
2013-03-21 |
Granata, Francesco |
Methods of making cells, tissues, and antibodies
|
|
CN102850454B
(zh)
*
|
2011-09-27 |
2014-06-25 |
上海博沃生物科技有限公司 |
抗呼吸道合胞病毒的人单克隆抗体
|
|
EP2586461A1
(de)
|
2011-10-27 |
2013-05-01 |
Christopher L. Parks |
Von einem eingehüllten Virus abgeleitete Virenpartikel
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
|
AU2012340174A1
(en)
|
2011-11-16 |
2014-05-29 |
Amgen Inc. |
Methods of treating epidermal growth factor deletion mutant VIII related disorders
|
|
CN104159922B
(zh)
|
2012-01-10 |
2018-03-02 |
比奥根Ma公司 |
对转运治疗性分子穿过血脑屏障的增强
|
|
US9796780B2
(en)
|
2012-05-14 |
2017-10-24 |
Biogen Ma Inc. |
LINGO-2 antagonists for treatment of conditions involving motor neurons
|
|
EP2679596B1
(de)
|
2012-06-27 |
2017-04-12 |
International Aids Vaccine Initiative |
HIV-1 Env-proteinvariante
|
|
WO2014003137A1
(ja)
*
|
2012-06-27 |
2014-01-03 |
旭化成メディカル株式会社 |
高アフィニティー抗体、及びその製造方法
|
|
BR112015009933A2
(pt)
*
|
2012-11-13 |
2017-12-12 |
Genentech Inc |
métodos de obtenção de uma população de plasmablastos, de enriquecimento de plasmablastos e de identificação de plasmablasto
|
|
EP2948478B1
(de)
|
2013-01-25 |
2019-04-03 |
Amgen Inc. |
Antikörper gegen cdh19 für melanome
|
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
|
CN104994725B
(zh)
|
2013-01-29 |
2022-07-01 |
巴斯夫植物科学有限公司 |
表达hcp6的抗真菌植物
|
|
CA2897482A1
(en)
|
2013-01-29 |
2014-08-07 |
Basf Plant Science Company Gmbh |
Fungal resistant plants expressing hcp7
|
|
WO2014118018A1
(en)
|
2013-01-29 |
2014-08-07 |
Basf Plant Science Company Gmbh |
Fungal resistant plants expressing ein2
|
|
TWI659968B
(zh)
|
2013-03-14 |
2019-05-21 |
再生元醫藥公司 |
針對呼吸道融合病毒f蛋白質的人類抗體及其使用方法
|
|
US9856313B2
(en)
|
2013-03-15 |
2018-01-02 |
Xiamen University |
Epitope of RSV fusion protein and antibody recognizing the same
|
|
UY35484A
(es)
|
2013-03-15 |
2014-10-31 |
Amgen Res Munich Gmbh |
Molécula de unión de cadena simple que comprenden ABP de extremo N
|
|
US9505849B2
(en)
|
2013-03-15 |
2016-11-29 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza M2 and CD3
|
|
SG11201505926VA
(en)
|
2013-03-15 |
2015-09-29 |
Biogen Ma Inc |
Factor ix polypeptide formulations
|
|
DK3012633T3
(en)
|
2013-06-21 |
2018-08-13 |
Alfresa Pharma Corp |
Immunochromatography device for detection of RSV
|
|
US20150065381A1
(en)
|
2013-09-05 |
2015-03-05 |
International Aids Vaccine Initiative |
Methods of identifying novel hiv-1 immunogens
|
|
EP3049521B1
(de)
|
2013-09-25 |
2019-03-06 |
Cornell University |
Verbindungen zur induzierung von antitumorimmunität und verfahren dafür
|
|
EP2873423B1
(de)
|
2013-10-07 |
2017-05-31 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
|
JP6317440B2
(ja)
|
2013-10-29 |
2018-04-25 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
酸化ストレスを阻害するための方法および組成物
|
|
WO2015070014A1
(en)
|
2013-11-08 |
2015-05-14 |
Biogen Idec Ma Inc. |
Procoagulant fusion compound
|
|
CR20160519A
(es)
|
2014-05-13 |
2017-01-27 |
The Trustees Of The Univ Of Pennysylvania |
Composiciones que comprenden avv que expresa constructos de anticuerpos duales y sus usos
|
|
ES2743809T3
(es)
|
2014-07-31 |
2020-02-20 |
Amgen Res Munich Gmbh |
Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
|
|
ES2980787T3
(es)
|
2014-07-31 |
2024-10-03 |
Amgen Res Munich Gmbh |
Constructo de anticuerpo de cadena sencilla biespecífico con distribución tisular potenciada
|
|
AR101669A1
(es)
|
2014-07-31 |
2017-01-04 |
Amgen Res Munich Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
|
WO2016112270A1
(en)
|
2015-01-08 |
2016-07-14 |
Biogen Ma Inc. |
Lingo-1 antagonists and uses for treatment of demyelinating disorders
|
|
BR112017016688B1
(pt)
|
2015-02-04 |
2024-01-23 |
Basf Plant Science Company Gmbh |
Método para aumentar a resistência fúngica, método para a produção de um produto e método para criar uma planta resistente a fungos
|
|
US10174292B2
(en)
|
2015-03-20 |
2019-01-08 |
International Aids Vaccine Initiative |
Soluble HIV-1 envelope glycoprotein trimers
|
|
EP3072901A1
(de)
|
2015-03-23 |
2016-09-28 |
International Aids Vaccine Initiative |
Lösliche hiv-1-hüllglykoproteintrimere
|
|
PL3283524T3
(pl)
|
2015-04-17 |
2023-06-12 |
Amgen Research (Munich) Gmbh |
Konstrukty biswoistego przeciwciała dla cdh3 i cd3
|
|
WO2016200543A2
(en)
|
2015-05-13 |
2016-12-15 |
The Trustees Of The University Of Pennsylvania |
Aav-mediated expression of anti-inluenza antibodies and methods of use thereof
|
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
|
JO3555B1
(ar)
|
2015-10-29 |
2020-07-05 |
Merck Sharp & Dohme |
جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
|
|
AR107582A1
(es)
|
2016-02-03 |
2018-05-16 |
Amgen Res Munich Gmbh |
Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t
|
|
UA126657C2
(uk)
|
2016-02-03 |
2023-01-11 |
Емджен Рісерч (Мюнік) Ґмбг |
ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font>
|
|
US10626126B2
(en)
*
|
2016-04-08 |
2020-04-21 |
Pulmocide Limited |
Compounds
|
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
|
EP3054014A3
(de)
|
2016-05-10 |
2016-11-23 |
BASF Plant Science Company GmbH |
Benutzung einer fungizids auf transgenen pflanzen
|
|
US11312761B2
(en)
*
|
2016-10-21 |
2022-04-26 |
Adimab, Llc |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
|
AU2017345786B2
(en)
|
2016-10-21 |
2024-08-01 |
Adimab, Llc |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
|
WO2018075954A2
(en)
|
2016-10-21 |
2018-04-26 |
Adimab, Llc |
Anti-respiratory syncytial virus antibodies, and methods of their generation and use
|
|
CR20190408A
(es)
|
2017-02-02 |
2020-01-31 |
Amgen Inc |
Composición farmacéutica de bajo ph que comprende construcciones de anticuerpos que activan linfocitos t antecedentes
|
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
|
TW201837170A
(zh)
|
2017-02-28 |
2018-10-16 |
賓州大學委員會 |
新穎aav媒介的流感疫苗
|
|
RS65241B1
(sr)
|
2017-02-28 |
2024-03-29 |
Univ Pennsylvania |
Vektor adeno-asociranih virusa (aav) iz podgrupe f i njegove upotrebe
|
|
TWI911431B
(zh)
|
2017-03-01 |
2026-01-11 |
英商梅迪繆思有限公司 |
抗rsv單株抗體配製物
|
|
MA48763A
(fr)
|
2017-05-05 |
2020-04-08 |
Amgen Inc |
Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés
|
|
EP3717632B1
(de)
|
2017-11-30 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Verfahren zur kultivierung von b-zellen
|
|
AU2018383679C1
(en)
|
2017-12-11 |
2026-05-28 |
Amgen Inc. |
Continuous manufacturing process for bispecific antibody products
|
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對muc17和cd3之雙特異性抗體構建體
|
|
WO2020025532A1
(en)
|
2018-07-30 |
2020-02-06 |
Amgen Research (Munich) Gmbh |
Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
|
|
BR112021002032A2
(pt)
|
2018-08-03 |
2021-07-20 |
Amgen Research (Munich) Gmbh |
construtos de anticorpos para cldn18.2 e cd3
|
|
PL3843757T3
(pl)
|
2018-08-27 |
2024-08-05 |
Affimed Gmbh |
Kriokonserwowane komórki nk wstępnie obciążone konstruktem przeciwciała
|
|
MX2021003976A
(es)
|
2018-10-11 |
2021-05-27 |
Amgen Inc |
Procesamiento posterior de constructos de anticuerpos biespecificos.
|
|
EP3938504A1
(de)
|
2019-03-11 |
2022-01-19 |
Basf Se |
Amylasen und verfahren zur herstellung und verwendung davon
|
|
US20220259547A1
(en)
|
2019-06-13 |
2022-08-18 |
Amgeng Inc. |
Automated biomass-based perfusion control in the manufacturing of biologics
|
|
US20220306741A1
(en)
|
2019-09-10 |
2022-09-29 |
Amgen Inc. |
Purification Method for Bispecific antigen-binding Polypeptides with Enhanced Protein L Capture Dynamic Binding Capacity
|
|
WO2021097344A1
(en)
|
2019-11-13 |
2021-05-20 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
|
IL293640A
(en)
|
2019-12-20 |
2022-08-01 |
Amgen Inc |
CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors
|
|
CA3160927A1
(en)
|
2019-12-27 |
2021-07-01 |
Affimed Gmbh |
Method for the production of bispecific fcyriii x cd30 antibody construct
|
|
US20230093169A1
(en)
|
2020-01-22 |
2023-03-23 |
Amgen Research (Munch) Gmbh |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
|
TW202200615A
(zh)
|
2020-03-12 |
2022-01-01 |
美商安進公司 |
用於治療和預防患者的crs之方法
|
|
CN115427454A
(zh)
|
2020-03-19 |
2022-12-02 |
安进公司 |
针对粘蛋白17的抗体及其用途
|
|
WO2021202463A1
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Anti-rsv antibodies
|
|
WO2021236638A1
(en)
|
2020-05-19 |
2021-11-25 |
Amgen Inc. |
Mageb2 binding constructs
|
|
JP2023527972A
(ja)
|
2020-05-29 |
2023-07-03 |
アムジエン・インコーポレーテツド |
Cd33及びcd3に結合する二重特異性コンストラクトの有害作用軽減投与
|
|
EP4225792A1
(de)
|
2020-10-08 |
2023-08-16 |
Affimed GmbH |
Trispezifische bindemittel
|
|
EP4240770A1
(de)
|
2020-11-06 |
2023-09-13 |
Amgen Research (Munich) GmbH |
Polypeptidkonstrukte mit selektiver bindung an cldn6 und cd3
|
|
AU2021373318A1
(en)
|
2020-11-06 |
2023-05-25 |
Amgen Inc. |
Antigen binding domain with reduced clipping rate
|
|
TW202225188A
(zh)
|
2020-11-06 |
2022-07-01 |
德商安美基研究(慕尼黑)公司 |
與cd3結合的多肽構建體
|
|
CA3200317A1
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Inc. |
Multitargeting bispecific antigen-binding molecules of increased selectivity
|
|
AR124216A1
(es)
|
2020-12-01 |
2023-03-01 |
Univ Pennsylvania |
Composiciones nuevas con motivos selectivos específicos del tejido y composiciones que las contienen
|
|
US20250282887A1
(en)
|
2021-04-02 |
2025-09-11 |
Amgen Inc. |
Mageb2 binding constructs
|
|
JP2024515788A
(ja)
|
2021-04-27 |
2024-04-10 |
ジェネレーション バイオ カンパニー |
治療抗体を発現する非ウイルスdnaベクター及びその使用
|
|
MX2023012931A
(es)
|
2021-05-06 |
2023-11-13 |
Amgen Res Munich Gmbh |
Moleculas de union a antigeno dirigidas a cd20 y cd22 para su uso en enfermedades proliferativas.
|
|
JP2024529381A
(ja)
|
2021-07-30 |
2024-08-06 |
アフィメド ゲーエムベーハー |
デュプレックスボディ
|
|
TW202334221A
(zh)
|
2021-11-03 |
2023-09-01 |
德商安富美德有限公司 |
雙特異性cd16a結合劑
|
|
WO2023079493A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
|
EP4493212A1
(de)
|
2022-03-14 |
2025-01-22 |
Generation Bio Co. |
Heterologe prime-boost-impfstoffzusammensetzungen und verfahren zur verwendung
|
|
AU2023268600A1
(en)
|
2022-05-12 |
2024-11-07 |
Amgen Research (Munich) Gmbh |
Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
|
|
AU2023343470A1
(en)
|
2022-09-14 |
2025-02-06 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
|
MX2025014635A
(es)
|
2023-06-14 |
2026-02-03 |
Amgen Inc |
Moleculas captadoras de enmascaramiento de celulas t
|
|
IL328264A
(en)
|
2023-11-14 |
2026-07-01 |
Janssen Pharmaceuticals Inc |
Anti-Respiratory Syncytial Virus Antibodies and Their Uses
|
|
CN120248057B
(zh)
*
|
2024-12-26 |
2025-12-02 |
北京华诺泰生物医药科技有限公司 |
一种呼吸道合胞病毒f蛋白突变体及其应用
|
|
WO2026161391A2
(en)
|
2025-01-21 |
2026-07-30 |
Bristol-Myers Squibb Company |
Cd19 binding molecules including cd3- and cd19- bispecific t cell engagers and related methods and uses
|